IMS 2022 | Emerging therapeutic strategies for patients with Waldenström’s macroglobulinemia
Steven Treon
• 25 Aug 2022
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, outlines exciting developments in the field of Waldenström’s macroglobulinemia (WM). Prof. Treon first highlights the growing role of BTK inhibitors in this space, especially in patients with comorbidities or patients who do not carry MYD88 mutations. Prof. Treon then comments on the potential of combining BTK inhibitors with CXCR4 antagonists, Bcl-2 inhibitors, or chemotherapy, and shares his excitement for the development of bispecific antibodies and CAR-T therapy in WM.
